Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-19
    E.g., 2018-09-19

Archive Search

4 results
6:18 PM, Jun 09, 2011  |  BC Extra | Company News

FDA issues warning on BPH drugs

FDA said it updated the labels for 5-alpha reductase inhibitors to include information about an increased risk …
high-grade prostate cancer. Proscar and Avodart are approved to treat benign prostatic hyperplasia (BPH). Other 5-alpha reductase
5:56 PM, Jan 27, 2011  |  BC Extra | Company News

Complete response for GSK's Avodart

abstentions, that the benefit-risk profile of Avodart did not support approval for the indication. The 5-alpha reductase
5:27 PM, Dec 01, 2010  |  BC Extra | Company News

ODAC rebuffs Proscar, Avodart for prostate cancer

the Prostate Cancer Prevention Trial (PCPT) suggesting the drug reduces risk of the disease. The 5-alpha reductase
5:36 PM, Jun 15, 2010  |  BC Extra | Company News

EC conditionally approves Votrient

men with an enlarged prostate. The company expects to launch the fixed-dose combination of a 5-alpha reductase